Surgical scar treatment: silicone, steroid, laser, and revision solve different scar problems

Silicone, corticosteroid injections, laser or light, and surgical scar revision are not interchangeable steps on one ladder. A postoperative scar first needs a feature map: age, whether the wound is fully closed, height, width, redness or pigment, texture, tethering, pain or itch, location, tension, infection or foreign-body concern, and whether it stays within the original wound. Treatment should target the dominant feature and its cause.¹²

A scar can be noticeable and still be in ordinary remodeling. It can also be hypertrophic, keloidal, widened, depressed, tethered, pigment-altered, painful, unstable, or affected by an unresolved wound problem. “Remove my scar” is therefore not a realistic procedure description: every surgical revision makes a new wound and scar.

Classify the feature before choosing the tool

The original operation and recovery are part of the diagnosis. Retrieve the operative note, closure method, postoperative wound events, infection or drainage history, path or implant records, nicotine exposure, tension or trauma, and prior scar treatments.

Silicone is a wound-stage decision

AAD describes silicone gel sheets or ointment for prevention and treatment of raised scars and warns against applying sheets to an open wound or scab.¹² The treating surgeon should set the start date because closure, drainage, adhesive reaction, skin fragility, and procedure location matter.

“Medical grade” is not enough to compare products. Record sheet versus gel, ingredients and adhesive, wear schedule, cleaning, duration, skin checks, and the endpoint. The Cochrane review found uncertainty in the comparative evidence base for treating hypertrophic scars, so a product should not promise scar erasure or a guaranteed percentage improvement.³

If skin becomes macerated, broken, or persistently irritated, contact the clinician rather than covering the problem for longer.

Steroid injections target selected raised scars

Intralesional corticosteroid can reduce height, hardness, itch, or pain in selected hypertrophic scars and keloids. It is not a general injection for a flat, wide, depressed, or lightly pigmented scar. AAD notes possible recurrence, skin thinning, and color change; clinicians may combine treatment with other injections or laser depending on the scar.¹²

Ask for the exact drug, concentration, volume, injection plane, interval, planned number of sessions, endpoint, and stopping rule. For darker skin, discuss both darkening and lightening risk. A before-and-after photograph should identify time since surgery and whether other treatments were used.

Laser is a family of mechanisms, not one scar treatment

A vascular laser can target redness; an ablative or fractional resurfacing system can target texture and remodeling; other wavelengths and settings may address pigment or thickness. The treatment can also create inflammation, pigment change, burns, or another scar if the platform, settings, operator, skin context, or aftercare is mismatched.

Require manufacturer, model, handpiece, wavelength, delivery pattern, FDA record, scar feature, test-area plan when relevant, endpoint, cooling, eye protection, number of sessions, and follow-up. Evidence for a pulsed-dye laser on a red hypertrophic scar does not validate an unspecified “laser scar package.”

The darker-skin laser guide explains why baseline tone, recent tanning, inflammation and pigment history, wavelength, settings, cooling, and test strategy belong in one plan.

Revision exchanges one scar configuration for another

Surgical scar revision may remove, realign, lengthen, break up, release, graft, or close a scar differently. It can improve a feature, but it cannot promise invisible skin. ASPS includes topical, injectable, resurfacing, and surgical approaches within scar revision rather than presenting surgery as the automatic final stage.⁴

Ask the surgeon to draw the new scar and explain:

• what feature the revision changes;
• why the scar widened, raised, tethered, or misaligned the first time;
• how tension, motion, blood supply, closure layers, and aftercare will differ;
• whether tissue expansion, graft, flap, or another operation is involved;
• pathology for any excised or uncertain tissue;
• recurrence risk and adjuvant treatment; and
• the earliest meaningful assessment horizon.

For keloids, excision alone can recur; AAD describes surgery as one component that is commonly paired with recurrence-reduction treatment.² A “cut it out” quote without an adjuvant plan is incomplete.

Some “scar” concerns need a different route

Persistent drainage, opening, increasing warmth or redness, fever, a new mass, exposed material, sudden pain, ulceration, rapid growth, or another changing finding should not be booked automatically as cosmetic resurfacing. A suture reaction, infection, foreign body, hernia, recurrent condition, implant problem, or unrelated lesion may require evaluation first.

Similarly, itch and pain deserve documentation rather than being treated only as appearance. Map the symptom, triggers, sensory change, movement restriction, and effect on function.

Build a longitudinal scar record

1. Confirm the wound stage and diagnosis. Separate open or unstable wound, ordinary remodeling, hypertrophic scar, keloid, pigment change, widening, depression, tethering, and another lesion.
2. Recover the cause record. Review the operation, closure, tension, infection, drainage, medicines, nicotine, trauma, sun, and prior treatment.
3. Choose one dominant endpoint. Measure height, width, redness, pigment, pliability, pain, itch, motion, or alignment instead of 'make it disappear.'
4. Match mechanism to feature. Specify silicone, drug injection, wavelength and settings, or surgical design and why it targets the endpoint.
5. Set the timeline and recurrence plan. Document sessions, review dates, photographs, stopping rules, combination sequence, and what happens if the scar returns.

End with a feature-to-treatment contract: name the scar’s age, color, height, width, tethering, pigment, symptoms, and suspected cause; identify the one feature the intervention targets; define the measurement and reassessment date; and record how recurrence risk will be managed.